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Abstract 
Alzheimefs diseaserelated mutations in the  ~resenilin-1  gene (PS11 are leadins to an elevated production of neuro- 
toxic ß-amyloid 1-42 and may additionally enhance oxidatiie Stress. Here. we provide in viv0 evidence indicating that 
brains of transgenic mice expressing different  human Alzheimer-linked PS1 mutations exhibit a reduced acüviiy of iwo 
antioxidant enzymes. For this purpose, mice transgenic for human PS1 and for  single and multiple PS1 mutations were 
generated. Mice with multiple PS1 mutations showed a significantlydecreased activiiyof theantioxidant enzymes CuIZn 
superoxide dismuiase and glulathione reductase already at an age of  3-4months.  As expected, this effect was less 
pronounced for the mice with a single PS1  mutation. By Contra-  animals beaiing normal human PSI showed sionifi- 
cantly elevated enzyme activities relative to non-transgenic liuermate controls.  L--  --  -  -C 
- 
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Sevetal mutalionsof ihepresen.%n-I  gene(PS1) masso- 
ciated with wly-onset familial Alzheimer's disease (FAD) 
(for review see [X]).  The finalpathogenic mechanism of PSI 
mutations remh  still unknown, but seems tobe  associated 
with altered protwlytic processing oP the amyloid precursor 
pmtein (APP). Seveml findings indicate that the prcduction 
of  rhe  amyioidogenic form of  &amyloid  (Aß)  1-12  is 
enbanoed in cells bnnsfected with PSI mutations as well 
as  in brains of nansgenic mice expressing mutant PS1 (3. 
Moreover, elevated levels of Aß were found in  plasma and 
fibmblasts from patienls with FAD-linked PS1 mutalions 
1131. 
Theprecisemechanisms  by which theseaiterations lead to 
neuradegeneration in Alzheimer's  die  (AD)  are still 
unknown.  Recent findings link the genemtion of reactis*e 
oxygenspecies(R0S) with amyloiddepoGtionandaggrega- 
tion as well as neuronal degeneration in AD. Synthetic Aß 
fmgnenlscan cause membme  iipid pmxidation as  well q 
an indpductionoPROS  [I]. Thefrecradical hypoth- 
esisof Aß cymtoxicily  is  hurher supporledby theprotection 
of neuronal cells subjected to  Aß ucament hy antioxidants, 
by inhibitors of oxidative eozyme metaboiism, or hy over- 
expression  of  supemxide  dismume  (SOD).  Moreover, 
reeent data indicale a specific role of üee radicals in  the 
pathomechanisrn of human PS1 muintions. Guo et al.  [9] 
demonsnated an increased oxyradical prcduction, enhsnced 
mitochondrial dysfunction and enhnnced sensitivity to lipid 
peroxidation (LPO) in primary hippowmpai neumns £mm 
PSI mutant hock-in mice (PSI M146V) &er  exposun? to 
Aß.  In the present communicalion we describe the genera- 
tion of three düierent types of ansgenic mice expressing 
either anomal  humanPS1 cransgene(PS1wt)oraPSl  ms- 
gene bearing a single pathogemc mutation at ccdon M146 
(PSI  M146L) ormultiple FAD-specific mulations M146L + 
H163R +  A246E +  L286V +  C410Y (PSI M5).  since the 
wmbination  of  different PSI  mutations shows additive 
effecls on Aßl-42  secretion [4].  We further addressed the 
question iP PSI mutaiions directly alter  the  activity of 
enzymes involved in lhe cellulnr defence mechanisms for 
oxidalive suess and whether this possible effect is more 
Conesponding author. Tel.:  +49-69-798-293-77: fax: +4969-  pmnOunced  in the psI M5 mice.  79829374. 
E-mailaddre+s:a.ecken@em.unl-franWun.de  IA. Ecken).  Mutagenesis of PSI was done using ihe SculptorTM in 
I  Present address: NAP AG,  Munich, Germany.  vit0  mutagencsis System (Amersham, Fmce). nie  wding region of PS1 was subcloned in Bluescript vector and muta-
tions were introduced using oligonucleotides containing the
desired mutation according to the protocol provided by the
manufacturer.
In the ®rst transgenic expression vector, on position 146,
methionin was replaced by leucin, this mutation leads to an
age of onset of 45 years in FAD patients [14]. In addition,
we created a new vector combining ®ve distinct FAD muta-
tions (M146L 1 H163R 1 A246E 1 L286V 1 C410Y) in
one expression construct (PS1 M5) [11]. The rationale
behind this was to amplify eventual phenotypes in the trans-
genic mice due to additive effects of the different mutations,
as it has been shown for the combination of two different
mutations in PS1 (M146L and L286V, which are also
included in the PS1 M5 mutations of the present study)
with an additive effect on the Ab42 production. For the
PS1 M5 construct subsequent rounds of mutagenesis were
performed. All mutated sequences were veri®ed by
sequence analysis [5].
Transgene expression is under the control of the human
HMG-CR-Promoter which represents a housekeeping-type
promoter that shows a strong and ubiquitous expression
pattern with high expression in neurons [6,7]. The method
ofgenerationandcharacterizationofPS1transgenicanimals
has been described previously [6,7]. Transgenic and non-
transgenic mice were littermates or subsequent generation
siblings and are therefore strain matched. PS1 transgenic
mice showed normal growth and development, and revealed
no apparent behavioural changes compared to littermate
controls. Life duration of transgenic mice was not changed.
The comparison of mutant transgenic lines to a wild type
line expressing normal human PS1 (PS1wt) suggested that
mutations in PS1, and not simple overexpression of the
transgene, were responsible for the cellular changes
described in the following.
As already shown by other studies, transgenic mice over-
expressing mutant PS1 show an elevation in Ab42, but they
do not develop amyloid deposits by 24 months of age [3,10].
This is in contrast to APP and APP/PS1 transgenic mice
[10]. Accordingly, PS1 M146L and PS1 M5 mice do not
develop amyloid plaques in the brain even at the age of
13 months [11]. Therefore, it is important to investigate
more subtle changes at the cellular level reported in the
present study.
For Western blotting, protein extracts from brain tissue of
transgenic (PS1wt, PS1 M146L and PS1 M5) or non-trans-
genic littermate control mice were prepared. After gel elec-
trophoresis (SDS-PAGE), PS1 proteins were identi®ed by
immunoblotting using the antibody MAB1563 (Chemicon).
Details of these assays have been described previously [7].
All mice were investigated at an age of 3±4 months and
were killed by decapitation. Brains were quickly removed
and tissue samples without cerebellum were homogenized.
Each of the following assays was performed with every
individual of each group of mice (non-transgenic mice:
n  15; mice transgenic for human PS1wt: n  10; PS1
M146L mice: n  10; PS1 M5 mice: n  7). Superoxide
dismutase (SOD) activity was measured using the SOD-
525 kit purchased by Calbiochem
w (Bad Soden, Germany)
according to the manufacturer's protocol. One SOD-525
activity unit is de®ned as the activity that doubles the auto-
xidation rate of the control blank (Vsample=Vcontrol  2).
Glutathione reductase (GR) activity was assayed using a
commercially available kit by Calbiochem
w. One GR unit
is de®ned as the reduction of 1 mM of glutathione per
minute at 258C and pH 7.6. Brain homogenates were incu-
bated with 100 mM FeCl3 (Merck, Darmstadt, Germany) or
buffer as control for 30 min at 378C. After centrifugation,
the supernatants were collected and tested for lipid perox-
idation (LPO) by measuring the concentration of malondial-
dehyde (MDA). The LPO-586 kit, purchased from
Calbiochem
w, was used for this purpose. This kit takes
advantage of a special chromogenic reagent which reacts
speci®cally with MDA at a comparatively low temperature
of incubation (458C). In order to assess whether human PS1
is expressed in the brain of the transgenic mice, we
performed Western blot analysis of brain homogenates
from transgenic mice and non-transgenic littermate
controls. The Western blot was probed with a monoclonal
antibody directed against the amino-terminal part of PS1.
This antibody is speci®c for human PS1 since no signal of
the endogenous PS1 is detectable in the homogenate of the
non-transgenic mice (Fig. 1, lane 4). All three different lines
of transgenic mice show clear expression of the transgene in
the brain. However, the proteolytic processing of transgenic
PS1 is different between constructs. The characteristic
amino-terminal fragment of PS1 is detectable in the brain
of mice expressing PS1 M146L and PS1 wt (Fig. 1, lane 2,
3) with the appearance of small amounts of full-length PS1
M146L most likely due to saturation of processing events as
described previously in transgenic mice and rats expressing
high amounts of PS1 [7,17]. However, multiple mutations in
PS1 M5 resulted in a clear reduction in the N-terminal frag-
ment and accumulation of full-length PS1 (Fig. 1, lane 1).
This is most likely not due to saturation of the processing
since the levels of PS1 M5 expression are lower than the
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Fig. 1. Western blot analysis of PS1 expression. Expression of
human PS1 is not observed in the brain of non-transgenic litter-
mate control mice (lane 4). The amino-terminal fragment of PS1
is detectable in all groups of transgenic mice (lane 1  PS1 M5;
lane 2  PS1 M146L; lane 3  PS1wt) whereas full-length PS1 is
only visible in mice expressing mutant PS1 (lane 1 and lane 2).levels of PS1wt or PS1 M146L protein. Instead, the accu-
mulation of full-length protein suggests that PS1 M5 has
severe structural alterations which make it no longer a
substrate for the presenilinase. It was previously reported
that some mutations in PS1 are able to alter the cleavage
pattern towards the increase of full-length protein in trans-
fected cells and it has been shown recently that in lympho-
cytes of FAD patients with PS1 mutations the PS1
proteolytic processing is impaired [16]. However, a correla-
tion between known pathological functions of presenilin
and proteolytic processing could yet not be clearly estab-
lished since the naturally occurring delta-exon 9 mutation is
not processed, due to the lack of the cleavage site, but still
leads to an increase in Ab1±42 production [15].
Furthermore, Western-blot analysis of the different trans-
genic lines with a polyclonal antibody against the amino-
terminus of PS1 (95/23, gift from C. Masters, Melbourne)
which in addition to the transgenic human PS1 also detected
the endogenous PS1 indicated that the levels of the trans-
genic PS1 slightly exceeded the level of endogenous murine
PS1 (data not shown) [11].
To elucidate the postulated relationship between PS1
mutation and oxidative stress, we investigated SOD activity
in PS1 transgenic mice. SOD is considered as a primary
defence against oxidative damage rapidly converting super-
oxide anion to hydrogen peroxide. Cytosolic superoxide
dismutase (Cu±Zn SOD) was signi®cantly decreased in
the brains of both types of transgenic mice carrying the
PS1 mutations as shown in Fig. 2A (ANOVA, P , 0:05).
The PS1 M146L mutation already reduced the activity of
SOD by about 20% vs. PS1wt. The multiple PS1 mutations
led to a further and signi®cant decrease of the enzymatic
activity of SOD (®nal reduction about 28%).
In addition, we examined the activity of GR which plays
an important part in the cellular antioxidant system by redu-
cing oxidized glutathione. Again, GR was signi®cantly
decreased over all three groups (ANOVA, P , 0:01).
Mice with multiple PS1 mutations showed a signi®cantly
decreased activity (about 27%) of the cerebral enzyme GR
compared to PS1wt and to PS1 M146L mice. However, the
difference in the reduction of GR activity between PS1wt
mice and PS1 M146L mice was less pronounced.
Basal levels of lipid peroxidation (LPO) measured by the
formation of MDA, were not signi®cantly different among
the examined groups of mice (PS1wt: 13.4 ^ 0.49; PS1
M146L, 12.9 ^ 0.61; PS1 M5: 13.29 ^ 0.97; data represent
concentration of MDA (nM/mg of protein) as means (SEM).
However, PS1 mutations seem to slightly increase the sensi-
tivity of brain cells to LPO after FeCl3 stimulation by 7%
(PS1 M146L) or 20% (PS1 M5) compared to PS1wt (see
Fig. 2C).
The combined results of the current study obtained with
three different transgenic lines are in line with ®ndings of a
completely independent study using hippocampal neurons
of PS1-knock-in-mice which show increased vulnerability
to lipid peroxidation when exposed to b-amyloid itself [9].
This also supports that the changes seen are resulting from
expression of human PS1 and mutant PS1, suggesting that
the transgenic integration site was not responsible, even if
our study used only one transgenic mouse line of each trans-
gene.
To determine whether overexpression of human PS1 links
protection or vulnerability to oxidative damage, we investi-
gated antioxidant enzyme activity and lipid peroxidation in
brains ofPS1wtmice andnon-transgenic littermatecontrols.
Basal levels of LPO did not differ between non-transgenic
littermates and mice expressing human PS1wt. In contrast,
PS1wt mice were signi®cantly less vulnerable to LPO
induced by FeCl3 than non-transgenic mice (see Table 1).
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Fig. 2. Effect of human presenilin-1 (PS1) mutations on lipid
peroxidation (LPO) and the antioxidant enzymes superoxide
dismutase (SOD) and glutathione reductase (GR) in mouse
brain. (A) Activity of the antioxidant enzyme SOD. Values repre-
sent the mean ^ SEM, n  7±10 animals. ANOVA indicated a
signi®cant effect over all groups (P , 0:05). Student's t-test: P ,
0:05 PS1wt vs. PS1 M5. (B) Activity of the antioxidant enzyme
GR. Values represent the mean ^ SEM, n  7±10 animals.
ANOVA indicated a signi®cant effect over all groups (P , 0:01).
Student's t-test: P , 0:05 PS1 M146L vs. PS1 M5; P  0:001
PS1wt vs. PS1 M5. (C) Effect of iron-stimulation on lipid perox-
idation, measured as an increase in the detected concentration
of MDA (nM of MDA per mg of protein). Values represent the
mean ^ SEM, n  7±11 animals.
Table 1
Effect of expression of human presenilin-1 on lipid peroxidation
and the antioxidant enzymes superoxide dismutase and















(DMDA nM/mg of protein)
13.37 ^ 0.95 9.23 ^ 0.81
d
a Data represent the effect of iron-stimulation on LPO
measured as D increase in the detected concentration of MDA
above basal levels. Statistical analysis was performed by
Student's t-test for independent samples.
b P , 0:05 compared with value for non-transgenic littermate
control. Values represent the mean ^ SEM, n  7±15 animals.
c P , 0:01 compared with value for non-transgenic littermate
control. Values represent the mean ^ SEM, n  10±15 animals.
d P , 0:01 compared with value for non-transgenic littermate
control. Values represent the mean ^ SEM, n  11±15 animals.Moreover, the activities of the antioxidant enzymes GR and
SODwere signi®cantlyenhanced (seeTable1).Thedetailed
role of human PS1 in neurons is still unknown, but there is
someevidencethatindicatesaprotectiveroleforthisprotein.
Roperch etal. [12] describedenhancedlevels ofapoptosisas
aresultofdownregulationofPS1intransfectedcells.Infact,
overexpression of PS1 even protects cortical neurons from
experimentallyinducedapoptosis[2].Thus,ourdatasupport
a protective effect of human PS1 and suggest a possible role
in the regulation of antioxidative defence mechanisms.
To our knowledge, this is the ®rst study showing in vivo
changes of antioxidant enzyme activities in brains from
transgenic mice bearing single or multiple PS1 mutations.
Consistent with the rationale that different PS1 mutations
within the same molecule cause more dysfunction and
higher Ab1±42 elevation than one alone [4], we found a
stronger impairment of antioxidant defence mechanisms in
PS1 M5 than in PS1 M146L mice. Although the mechanism
by which mutated PS1 exerts these effects require further
studies, our data indicate an important defect induced by
PS1 mutations, which very likely contributes to the
enhanced vulnerability for neurodegeneration.
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